专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2018175449A1 PROLINE AMIDE COMPOUNDS AND THEIR AZETIDINE ANALOGUES CARRYING A SPECIFICALLY SUBSTITUTED BENZYL RADICAL 审中-公开
公开(公告)号：WO2018175449A1
公开(公告)日：2018-09-27
申请号：PCT/US2018/023376
申请日：2018-03-20
申请人： ABBVIE DEUTSCHLAND GMBH & CO. KG , ABBVIE INC.
发明人： BACKFISCH, Gisela , BAKKER, Margaretha , BLACK, Lawrence , BRAJE, Wilfried , DRESCHER, Karla , ERHARD, Thomas , HAUPT, Andreas , HOFT, Carolin , KLING, Andreas , LAKIS, Viktor , MACK, Helmut , RELO, Ana Lucia
IPC分类号： C07D401/12 , C07D405/12 , C07D207/16 , A61P25/24 , A61P25/14 , A61P9/00 , A61P25/22 , A61P25/28 , A61P25/18 , A61P25/30 , A61P3/10 , A61K31/40
摘要： The present invention relates to proline amide compounds and their azetidine derivatives of formula I wherein the variables are as defined in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT 2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT 2C receptor, to a method for preventing or treating conditions and disorders which respond to the modulation of the 5-HT 2C receptor, and processes for preparing such compounds and compositions.

2. 发明申请

WO2014041131A1 TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES 审中-公开
标题翻译：三元喹啉和喹啉衍生物
公开(公告)号：WO2014041131A1
公开(公告)日：2014-03-20
申请号：PCT/EP2013/069036
申请日：2013-09-13
申请人： ABBVIE DEUTSCHLAND GMBH & CO. KG , ABBVIE INC.
发明人： KOOLMAN, Hannes , BRAJE, Wilfried , MACK, Helmut , HAUPT, Andreas , RELO, Ana Lucia , DRESCHER, Karla , BAKKER, Margaretha Henrica Maria , LAKICS, Viktor , HOFT, Carolin , XU, Ruxu , ZHAO, Xiaona
IPC分类号： C07D471/06 , C07D487/06
CPC分类号： C07D471/06 , C07D487/06 , C07D487/16
摘要： The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT 2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT 2C receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT 2C receptor.
摘要翻译：本发明涉及三环喹啉和喹喔啉衍生物，涉及含有这些化合物的药物组合物，其用作5-HT 2C受体的调节剂，特别是激动剂或部分激动剂，其用于制备用于预防或治疗响应于5-HT 2C受体的调节的病症和病症，以及用于预防或治疗对5-HT 2C受体的调节作出反应的病症和障碍的方法。

3. 发明申请

WO2014140246A1 ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR 审中-公开
标题翻译：适用于治疗多巴胺D3受体调节障碍的ACYLAMINOCOCLOALKYL化合物
公开(公告)号：WO2014140246A1
公开(公告)日：2014-09-18
申请号：PCT/EP2014/055062
申请日：2014-03-14
申请人： ABBVIE DEUTSCHLAND GMBH & CO. KG , ABBVIE INC.
发明人： HAUPT, Andreas , DINGES, Jürgen , UNGER, Liliane , WICKE, Karsten , VAN WATERSCHOOT, Robert , DRESCHER, Karla , RELO, Ana Lucia
IPC分类号： C07D239/42 , A61K31/506 , A61P25/00
CPC分类号： C07D295/155 , A61K31/496 , C07D239/42 , C07D403/04
摘要： The present invention relates to novel acylaminocycloalkyl compounds, in particular to the compounds of the formula I as described herein and to their salts and N-oxides. The compounds possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of the dopamine D3 receptor. In formula I, the variables have the following meanings: m is 1 or 2, n is 1 or 2, A is selected from the group consisting of CH 2 , CH 2 CH 2 , CHFCH 2 and CF 2 CH 2 , R 1 is an oxygen containing cyclic radical selected such as C 3 -C 6 cycloalkyl, which carries one or two oxygen containing radicals selected from the group consisting of OH, C 1 -C 2 -alkoxy, fluorinated C 1 -C 2 -alkoxy, and a carbonyl oxygen,, R 2 is selected from the group consisting of hydrogen, OH and fluorine, R 3a is selected from the group consisting of hydrogen and methyl, R 3b is selected from the group consisting of hydrogen and methyl, R 4 is branched C 4 -C 6 alkyl or branched fluorinated C 4 -C 6 alkyl, and R 5 is inter alia C 1 -C 6 alkyl, fluorinated C 1 -C 3 alkyl, C 1 -C 2 -alkoxy-C 1 -C 4 -alkyl, fluorinated C 1 -C 2 -alkoxy-C 1 -C 4 -alkyl, hydroxy-C 1 -C 4 -alkyl, fluorinated hydroxy-C 1 -C 4 -alkyl, oxetanyl, fluorinated oxetanyl, oxolanyl, fluorinated oxolanyl, C 3 -C 5 cycloalkyl, fluorinated C 3 -C 5 cycloalkyl, etc.
摘要翻译：本发明涉及新的酰氨基环烷基化合物，特别是涉及本文所述的式I化合物及其盐和N-氧化物。该化合物具有有价值的治疗性质，特别适用于治疗对多巴胺D3受体调节作出反应的疾病。在式I中，变量具有以下含义：m为1或2，n为1或2，A选自CH 2，CH 2 CH 2，CHFCH 2和CF 2 CH 2，R 1为选自氧的环状基团，例如C 3 -C 6环烷基，其携带一个或两个选自OH，C 1 -C 2烷氧基，氟化C 1 -C 2烷氧基和羰基氧的含氧基团，R 2选自氢，OH 和氟，R3a选自氢和甲基，R3b选自氢和甲基，R4是支链C4-C6烷基或支链氟化C4-C6烷基，R5特别是C1-C6 烷基，氟化C 1 -C 3烷基，C 1 -C 2烷氧基-C 1 -C 4烷基，氟化C 1 -C 2烷氧基-C 1 -C 4 - 烷基，羟基-C 1 -C 4 - 烷基，氟化羟基-C 1 -C 4烷基，氧杂环丁烷基，氟化氧杂环丁烷基，氧杂环戊烷基，氟代氧杂环戊烷基，C3-C5环烷基，氟化C3-C5环烷基等

4. 发明授权

EP2432769B1 N-PHENYL-(PIPERAZINYL OR HOMOPIPERAZINYL)-BENZENESULFONAMIDE OR BENZENESULFONYL-PHENYL-(PIPERAZINE OR HOMOPIPERAZINE) COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR 有权
标题翻译： N-苯基（哌嗪基或高哌嗪基）-BENZOLSULFONAMID- OR苯磺酰基苯基 - （哌嗪或高哌嗪）的化合物，用于治疗血清素5-HT6受体调节疾病的吸引力
公开(公告)号：EP2432769B1
公开(公告)日：2015-04-01
申请号：EP10719748.5
申请日：2010-04-29
申请人： AbbVie Deutschland GmbH & Co KG , AbbVie Inc.
发明人： HAUPT, Andreas , POHLKI, Frauke , DRESCHER, Karla , WICKE, Karsten , UNGER, Liliane , RELO, Ana-Lucia , BESPALOV, Anton , VOGG, Barbara , BACKFISCH, Gisela , DELZER, Juergen , ZHANG, Min , LAO, Yanbin
IPC分类号： C07D241/04 , C07D317/06 , C07D295/096 , A61K31/495 , A61P25/18 , A61P25/28 , A61P25/30
CPC分类号： C07D295/096 , C07D241/04 , C07D243/08 , C07D317/46

6. 发明授权

EP2970146B1 ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR 有权
标题翻译：适用于治疗应答多巴胺D3受体调节的疾病的酰胺基环酰基化合物
公开(公告)号：EP2970146B1
公开(公告)日：2017-11-01
申请号：EP14710261.0
申请日：2014-03-14
申请人： AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.
发明人： HAUPT, Andreas , DINGES, Jürgen , UNGER, Liliane , WICKE, Karsten , VAN WATERSCHOOT, Robert , DRESCHER, Karla , RELO, Ana Lucia
IPC分类号： C07D239/42 , C07D403/04 , A61K31/506 , A61P25/00
CPC分类号： C07D295/155 , A61K31/496 , C07D239/42 , C07D403/04

7. 发明授权

EP2909201B1 ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR 有权转让
标题翻译： ACYLAMINOCYCLOALKYLVERBINDUNGEN FOR疾病对调制多巴胺D 3受体应答的治疗
公开(公告)号：EP2909201B1
公开(公告)日：2017-02-22
申请号：EP13785389.1
申请日：2013-10-21
申请人： AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.
发明人： HAUPT, Andreas , DINGES, Jürgen , UNGER, Liliane , WICKE, Karsten , VAN WATERSCHOOT, Robert , MITTELSTADT, Scott , DRESCHER, Karla , RELO, Ana
IPC分类号： C07D405/14 , C07D403/04 , C07D405/04 , C07D239/42 , A61K31/506 , A61P25/00
CPC分类号： C07D239/26 , C07D239/42 , C07D403/04 , C07D405/04 , C07D405/14

8. 发明公开

EP2970146A1 ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR 有权
标题翻译： ACYLAMINOCYCLOALKYLVERBINDUNGEN FOR疾病对调制多巴胺D 3受体应答的治疗
公开(公告)号：EP2970146A1
公开(公告)日：2016-01-20
申请号：EP14710261.0
申请日：2014-03-14
申请人： AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.
发明人： HAUPT, Andreas , DINGES, Jürgen , UNGER, Liliane , WICKE, Karsten , VAN WATERSCHOOT, Robert , DRESCHER, Karla , RELO, Ana Lucia
IPC分类号： C07D239/42 , A61K31/506 , A61P25/00
CPC分类号： C07D295/155 , A61K31/496 , C07D239/42 , C07D403/04
摘要： The present invention relates to novel acylaminocycloalkyl compounds, in particular to the compounds of the formula I as described herein and to their salts and N-oxides. The compounds possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of the dopamine D3 receptor. In formula I, the variables have the following meanings: m is 1 or 2, n is 1 or 2, A is selected from the group consisting of CH
2 , CH
2 CH
2 , CHFCH
2 and CF
2 CH
2 , R
1 is an oxygen containing cyclic radical selected such as C
3 -C
6 cycloalkyl, which carries one or two oxygen containing radicals selected from the group consisting of OH, C
1 -C
2 -alkoxy, fluorinated C
1 -C
2 -alkoxy, and a carbonyl oxygen,, R
2 is selected from the group consisting of hydrogen, OH and fluorine, R
3a is selected from the group consisting of hydrogen and methyl, R
3b is selected from the group consisting of hydrogen and methyl, R
4 is branched C
4 -C
6 alkyl or branched fluorinated C
4 -C
6 alkyl, and R
5 is inter alia C
1 -C
6 alkyl, fluorinated C
1 -C
3 alkyl, C
1 -C
2 -alkoxy-C
1 -C
4 -alkyl, fluorinated C
1 -C
2 -alkoxy-C
1 -C
4 -alkyl, hydroxy-C
1 -C
4 -alkyl, fluorinated hydroxy-C
1 -C
4 -alkyl, oxetanyl, fluorinated oxetanyl, oxolanyl, fluorinated oxolanyl, C
3 -C
5 cycloalkyl, fluorinated C
3 -C
5 cycloalkyl, etc.
摘要翻译：本发明涉及新颖的化合物acylaminocycloalkyl，特别是我在和它们的盐和N-氧化物中描述的下式的化合物。这些化合物具有有价值的治疗性质和是合适的，特别是用于治疗疾病并于多巴胺D3受体的调节有反应的。 2 1或2，m是1或，n为A的选自CH 2，CH 2 CH 2，CHFCH2和CF 2 CH 2的选择，R 1是含有氧的环状基团中选择检查作为C3：在式I中，变量具有以下含义 C6环烷基，其携带选自OH中选择的一个或两个氧含有自由基，C1-C2烷氧基，氟化的C 1 -C 2 - 烷氧基，和具有羰基氧，R 2是选自氢由......组成，OH和氟，R 3A为选自氢和甲基中选择，R 3b中选自氢和甲基中选择，R 4是支链的C4-C6烷基或支链氟代C 4 -C 6烷基，而R5是尤其C1-C6烷基，C1-C3氟代烷基，C1-C2烷氧基-C 1 -C 4 - 烷基，氟化的C 1 -C 2 - 烷氧基-C 1 -C 4 - 烷基，羟基-C 1 -C 4 - 烷基，氟化的羟基-C 1 -C 4 - 烷基，氧杂环丁烷基，氟化氧杂环丁基，氧杂环戊基，氧杂环戊基氟化，C3-C5环烷基，氟化的C 3 -C 5环烷基，等等。

9. 发明公开

EP2895485A1 TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES 审中-公开
标题翻译： TRICYCLISCHE CHINOLIN- UND CHINOXALINDERIVATE
公开(公告)号：EP2895485A1
公开(公告)日：2015-07-22
申请号：EP13762483.9
申请日：2013-09-13
申请人： AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.
发明人： KOOLMAN, Hannes , BRAJE, Wilfried , MACK, Helmut , HAUPT, Andreas , RELO, Ana Lucia , DRESCHER, Karla , BAKKER, Margaretha Henrica Maria , LAKICS, Viktor , HOFT, Carolin , XU, Ruxu , ZHAO, Xiaona
IPC分类号： C07D471/06 , C07D487/06
CPC分类号： C07D471/06 , C07D487/06 , C07D487/16
摘要： The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.
摘要翻译：本发明涉及三环喹啉和喹喔啉衍生物，涉及含有这些化合物的药物组合物，其用作5-HT 2C受体的调节剂，特别是激动剂或部分激动剂，其用于制备预防或治疗对5-HT 2C受体的调节作出反应的病症和障碍，以及用于预防或治疗对5-HT 2C受体调节作用的病症和障碍的方法。

10. 发明申请

WO2017089458A1 HEXAHYDROPYRAZINOBENZ- OR -PYRIDO-OXAZEPINES CARRYING AN OXYGEN-CONTAINING SUBSTITUENT AND USE THEREOF IN THE TREATMENT OF 5-HT2C-DEPENDENT DISORDERS 审中-公开
标题翻译：携带含氧取代基的六氢吡嗪或哌啶氧杂吖嗪类化合物及其在治疗5-HT2C依赖性疾病中的用途
公开(公告)号：WO2017089458A1
公开(公告)日：2017-06-01
申请号：PCT/EP2016/078670
申请日：2016-11-24
申请人： ABBVIE DEUTSCHLAND GMBH & CO. KG
发明人： BACKFISCH, Gisela , BAKKER, Margaretha Henrica Maria , BLAICH, Günter , BRAJE, Wilfried , DRESCHER, Karla , ERHARD, Thomas , HAUPT, Andreas , HOFT, Carolin , LAKICS, Viktor , MACK, Helmut , OELLIEN, Frank , PETER, Raimund , RELO, Ana Lucia
IPC分类号： C07D498/04 , C07D498/14 , A61K31/553 , A61P25/24
CPC分类号： C07D498/04 , C07D498/14
摘要： The present invention relates to compound of formula (I) (I) wherein the variables are as defined in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT 2C receptor, to their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT 2C receptor, and to methods for preventing or treating conditions and disorders which respond to the modulation of 5-HT 2C receptor.
摘要翻译：本发明涉及式（I）（I）的化合物，其中变量如权利要求和描述中所定义。本发明进一步涉及含有这些化合物的药物组合物，它们作为5-HT 2C受体的调节剂，特别是激动剂或部分激动剂的用途，它们用于制备用于预防或治疗对5-HT 2C受体调节作出反应的病症和障碍，以及预防或治疗对5-HT 2C /β调节作出反应的病症和障碍的方法 >受体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式